DENTSPLY SIRONA (XRAY, $41.09) Soars +13.37% as Top Gainer in Medical Specialties Industry
This AI trading robot, available at Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA), was a top performer in our robot factory, generating 21% for XRAY over the past 6 months.
DENTSPLY SIRONA (XRAY, $41.09) was one of the top gainers in the medical specialties industry this month, soaring +13.37% to $41.09 per share. The company's stock moved above its 50-day moving average on March 24, 2023, signaling a shift from a downward trend to an upward trend. With an impressive 73% chance of continued upward momentum, investors are paying close attention to XRAY's recent success.
Industry Analysis
A.I.dvisor analyzed 501 stocks in the medical specialties industry for the month ending April 21, 2023. It discovered that 413 of them (82.47%) exhibited an uptrend, while 88 of them (17.53%) exhibited a downtrend. This bullish industry-wide trend, with over 82% of stocks in an uptrend, sets a positive tone for XRAY's performance.
Technical Analysis
XRAY's recent move above its 50-day moving average on March 24, 2023, is a significant technical indicator. This shift suggests that the stock is moving from a downward trend to an upward trend, which is generally seen as a bullish signal. In 32 of 44 similar past instances, the stock price increased further within the following month. Based on this historical data, the odds of a continued upward trend are 73%.
Earnings Results
DENTSPLY SIRONA's upward trend can be attributed to several factors, including strong earnings results. The company's financial performance indicates that it is well-positioned to capitalize on the positive momentum in the medical specialties industry. As XRAY continues to innovate and expand its product offerings, investors can expect the stock to remain an attractive option in this thriving market sector.
DENTSPLY SIRONA's impressive +13.37% gain this month is a testament to the company's strong position within the medical specialties industry. As the stock continues to rise above its 50-day moving average, investors have reason to be optimistic about XRAY's future performance. With a 73% chance of continued upward momentum, the stock is poised for further growth, making it an appealing investment opportunity for those looking to capitalize on the bullish trend in the medical specialties sector.
XRAY in upward trend: price rose above 50-day moving average on May 08, 2025
XRAY moved above its 50-day moving average on May 08, 2025 date and that indicates a change from a downward trend to an upward trend. In of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 23, 2025. You may want to consider a long position or call options on XRAY as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on April 21, 2025. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XRAY broke above its upper Bollinger Band on May 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on April 23, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.032) is normal, around the industry mean (24.089). P/E Ratio (19.231) is within average values for comparable stocks, (79.080). Projected Growth (PEG Ratio) (1.574) is also within normal values, averaging (5.667). Dividend Yield (0.018) settles around the average of (0.018) among similar stocks. P/S Ratio (1.725) is also within normal values, averaging (42.249).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XRAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a global denal eqipment company
Industry MedicalSpecialties